Bausch Health Companies Inc. announced that Dr. Yehia Hashad will join Bausch + Lomb Corporation ("Bausch + Lomb") as executive vice president of Research & Development (R&D) and chief medical officer (CMO) effective Jan. 31, 2022. Dr. Hashad will join Bausch + Lomb from Allergan/AbbVie, where for the past 11 years he held various roles, including leading Allergan's global clinical development program for its eye care portfolio.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
7.62 USD | +0.93% | +4.10% | -4.99% |
07-10 | Raymond James Initiates Bausch Health at Market Perform Rating | MT |
06-21 | Bausch Health Sues Norwich for Patent Infringement Over Application for Generic Version of IBS Drug | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-4.99% | 2.75B | |
+55.35% | 815B | |
+32.63% | 597B | |
-0.10% | 377B | |
+15.47% | 319B | |
+13.10% | 310B | |
+16.42% | 247B | |
+14.74% | 228B | |
+16.54% | 180B | |
+4.31% | 170B |
- Stock Market
- Equities
- BHC Stock
- News Bausch Health Companies Inc.
- Bausch Health Companies Inc. Appoints Yehia Hashad as Executive Vice President of Research & Development (R&D) and Chief Medical Officer Effective Jan. 31, 2022